SAN DIEGO, May 24, 2018 /PRNewswire/ -- Bloom Science, a biotechnology company accelerating the development of a new class of neuroprotective medicines, today announced that it has secured an exclusive technology license around preclinical research demonstrating that gut bacteria play a critical role in the anti-seizure effects of the ketogenic diet. The research was published

Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. USL2611 already granted orphan drug and fast

John Somoza, Ph.D. presented on behalf of the Translational Epilepsy Network at the Shark Tank Competition at the 2018 Epilepsy Pipeline Conference. Although we did not win, our presentation generated a lot of interest, especially among people working at pharmaceutical companies that target epilepsy and among people interested in investing in ideas to treat epilepsy.

VIMPAT® (lacosamide) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures (POS)1 Pediatric epilepsy is the most common, serious, treatable neurological disorder among children and young adults, thought to affect about 470,000 children in the U.S. as of 20152,3   VIMPAT pediatric approval

Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints Zogenix to Host Conference Call Today at 8:30 AM Eastern Time/5:30 AM Pacific Time EMERYVILLE, Calif., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc.(NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment

Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy SUMMIT, N.J., Sep. 27, 2017 – Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round.